[en] The goal of this project was to find and collect high concentrations of endotoxin-specific antibodies for therapeutic IgG- or IgM-enriched preparations. Various enzyme-linked immunosorbent assays (ELISAs) were developed to perform longitudinal studies of the serological response to a large panel of smooth and rough purified lipopolysaccharide (LPS) extracts in a population of healthy blood donors. To accomplish this, 1612 human serum samples from volunteer blood donors collected by seven different blood banks in Belgium were screened and specific IgM and IgG activities were measured. Approximately 17% of the donors had anti-LPS concentrations higher than 40 mg L-1. Of these, 10.9% had anti-smooth LPS antibodies, 3.7% had anti-rough LPS antibodies and 2.8% were found to be positive towards both types of LPS. The mean anti-LPS antibody concentration was 8 mg L-1 for rough LPS and 14 mg L-1 for smooth LPS. Age- and sex-related distributions of the activities indicated that the greatest prevalence of high anti-LPS concentration was in women aged 40-49 years and in men older than 60 years. Differential absorption experiments showed that the pooled serum of selected blood donors contained a mixture of specific and cross-reacting antibodies. We detected predominantly anti-LPS activities due to the IgG1 and IgG2 subclasses. The range of specificities to different LPS was increased by the pooling of selected sera. It was concluded that pools of naturally occurring specific anti-LPS immunoglobulin antibodies may be obtained in Belgium by screening blood donors using ELISAs that we have developed.
Disciplines :
Anesthesia & intensive care
Author, co-author :
Nys, Monique ; Centre Hospitalier Universitaire de Liège - CHU > Soins intensifs
Laub, R.
Damas, Pierre ; Université de Liège - ULiège > Soins intensifs
Sondag, Danièle ; Université de Liège - ULiège > Département des sciences de la santé publique > Immunohématologie - Transfusion
Goethals, T.
Jamaer, D.
Joassin, L.
Lamy, Maurice ; Université de Liège - ULiège > Département des sciences cliniques > Anesthésie et réanimation
Language :
English
Title :
Screening and characterization of specific anti-lipopolysaccharide antibodies in Belgian blood donors by enzyme-linked immunosorbent assays
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
Bryan CS, Reynolds KL, Brenner ER. Analysis of 1186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev Infect Dis 1983;5:629-38.
Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia IV: re-evaluation of clinical features and treatment in 612 patients. Am J Med 1980;68:344-55.
Wenzel RP, Andriole VT, Bartlett JG et al. Antiendotoxin monoclonal antibodies for gram-negative sepsis: guidelines from the IDSA. Clin Infect Dis 1992;14:973-6.
Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. The Methylprednisolone Severe Sepsis Study Group. A controlled clinical trial of high dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317:653-8.
Bone RC. Sepsis and multiple organ failure: consensus and controversy. In: Lamy M, Thijs LG, eds. Mediators of sepsis. Update in Intensive Care and Emergency Medicine, Vol. 16. Berlin: Springer, 1992;3-12.
Greenman RL, Schein RMH, Martin MA, Wenzel RP, Macintyre NR. The XOMA Sepsis Study Group. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991;266:1097-102.
Parker MM, Parrillo JE. Septic shock: hemodynamics and pathogenesis. JAMA 1983;250:3324-7.
Ziegler EJ, McCutchan JA, Fierer J et al. Treatment of gram-negative bacteremia and shock with human antiserum to mutant Excherichia coli. N Engl J Med 1982;307:1225-30.
Ziegler EJ, Fisher CJ Jr., Sprung CL et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin a randomized, double-bind, placebo-controlled trial. N Engl J Med 1991;324: 429-36.
Parillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993;328:1471-7.
Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JE. Endotoxemia in human septic shock. Chest 1991; 99:169-75.
Van Deventer SJH, Büller HR, Ten Cate JW, Sturk A, Pauw W. Endotoxemia: an early predictor of septicemia in febrile patients. Lancet 1988;1:605-9.
Dofferhoff ASM, Buys J. Effects of antibiotics on endotoxin release. In: Vincent J-L, ed. Yearbook of Intensive Care and Emergency Medicine. Berlin: Springer, 1995:465-72.
Shenep JL, Mogan KA. Kinetics of endotoxin release during antibiotic therapy for experimental gram-negative bacterial sepsis. J Infect Dis 1984;150:380-8.
Nys M, Damas P, Joassin L, Lamy M. Sequential anti-core glycolipid immunoglobulin antibody activities in patients with and without septic shock and their relation to outcome. Am Surg 1993;217:300-6.
Nys M, Joassin L, Somzee A, Demonty J. Enzyme-linked immunosorbent assay for immunoglobulin C subclass antibodies specific for enterobacterial Re core glycolipid in healthy individuals and in patients infected by gram-negative bacteria. J Clin Microbiol 1988;26:857-62.
Calandra T, Glauser MP, Schellekens J, Verhoef J. The Swiss-Dutch J5 Immunoglobulin Study Group. Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized study. J Infect Dis 1988;158:312-9.
The Intravenous Immunoglobulin Collaborative Study Group. Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high-risk of postsurgical infection. N Engl J Med 1992;327:234-40.
Fomsgaard A, Nielsen R, Froberg KD, Baek L, Deghn HK. Endotoxinaemia in toxic shock syndrome treated with anti-endotoxin antibodies. Lancet 1987;1:514-5.
Fomsgaard A, Baek L, Fomsgaard JS, Engquist A. Preliminary study on treatment of septic shock patients with antilipopolysaccharide IgG from blood donors. Scand J Infect Dis 1989;21:697-708.
Fomsgaard A. Therapeutic anti-LPS IgG obtained by screening of blood donors (abstract). Circ Shock 1991;34:120.
Lachman E, Pitsoe SB, Gaffin SL. Anti-lipopolysaccharide (anti-LPS) immunotherapy in the management of septic shock of obstetrical and gynaecological origin. Lancet 1984;1: 981-3.
Schedel I, Dreikhausen U, Nentwig B et al. Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clincial trial. Crit Care Med 1991;19: 1104-13.
Glinz W, Grob PJ, Nydegger UE, Ricklin T, Stamm F, Stoffel D, Lasance A. Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients with multiple trauma. Int Care Med 1985;11:288-94.
Zanetti G, Glauser MP, Baumgartner JD. Use of immunoglobulins in prevention and treatment of infection in critically ill patients: review and critique. Rev Infect Dis 1991;13:985-92.
Calandra T, Baumgartner JD. Anti-endotoxin therapy. In: Sibbald WJ, Vincent J-L, eds. Clinicl trials for the treatment of sepsis. Update in Intensive Care and Emergency Medicine, Vol. 19. Berlin: Springer, 1995:237-50.
Fisher CJ, Cook DJ. Critical evaluation of the design and conduct of preivous clinical trials in sepsis. In: Sibbald WJ, Vincent J-L, eds. Clinical trials for the treatment of sepsis. Update in Intensive Care and Emergency Medicine, Vol. 19. Berlin: Springer, 1995:317-28.
Opal SM. Clinical trials of novel therapeutic agents: why did they fail? In: Vincent J-L, ed. Yearbook of Intensive Care and Emergency Medicine. Berlin: Springer, 1995:425-36.
Westphal O, Jann K. Bacterial lipopolysaccharides. Extraction with phenol water and further applications of the procedure. In: Whistler RL, Wolfrom ML, eds. Methods of Carbohydrate Chemistry, Vol. V. New York: Academic Press, 1965:83-7.
Galanos C, Lüderitz O, Westphal O. A new method for the extraction of R lipopolysaccharides. Eur J Biochem 1969;9: 245-9.
Chang CM, Nowotny A. Relation of structures to function in bacterial O antigens. VII. Endotoxicity of lipid A. Immunochemistry 1975;12:19-28.
Gaffin SL, Grinberg Z, Abraham C, Birkham J, Shechter Y. Protection against hemorrhagic shock in the cat by human plasma containing endotoxin-specific antibodies. J Surg Res 1981;31:18-21.
Lowry OH, Rosebrough NJ, Farr AL, Randall RL. Protein measurements with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
Barclay GR, Scott BB. Serological relationships between Escherichia coli and Salmonella smooth- and rough-mutant lipopolysaccharides as revealed by enzyme-linked immunosorbent assay for human immunoglobulin G antiendotoxin antibodies. Infect Immun 1987;55:2706-14.
Fomsgaard A, Zhang G-H, Shand GH, Bendtzen K, Back L. Immunochemical and biological reactivity of human antilipopolysaccharide IgG obtained by screening of blood donors. Scand J Immunol 1989;29:309-16.
Law BJ, Marks MI. Age-related prevalence of human serum IgG and IgM antibody to the core glycolipid of Escherichia coli strain J5, as measured by ELISA. J Infect Dis 1985;151:988-94.
Mattsby-Baltzer I, Alving CR. Antibodies to lipid A: occurrence in humans. Rev Infect Dis 1984;6:553-7.
Nys M, Damas P, Damas F, Joassin L, Demonty J. A direct enzyme-linked immunosorbent assay (ELISA) for antibodies to enterobacterial Re core glycolipid and lipid A. Med Microbiol Immunol 1987;176:257-71.
Stoll BJ, Pollack M, Hooper JA. Antibodies to endotoxin core determinants in normal subjects and in immune globulins for intravenous use. Serodiag Immunother Infect Dis 1987;1:21-31.
Jacob AI, Goldberg PK, Bloom N, Degenshein GA, Kozinn PJ. Endotoxin and bacteria in the portal blood. Gastroenterology 1977;72:1268-70.
Fomsgaard A, Dinesen BO, Baek L. Anti-lipopolysaccharide antibodies measured by enzyme-immunoassay in Danish blood donors. Acta Pathol Microbiol Immunol Scand Sect C 1987; 95:9-13.
Gaffin SL. Large-scale production of anti-gram-negative bacteria antibodies. Lancet 1983;2:1420.
Mattsby-Baltzer I, Claësson I, Hanson LA et al. Antibodies to lipid A during urinary tract infection. J Infect Dis 1981;144: 319-28.
Hamilton-Davies C. The effect of monovalent thyphoïd vaccine on endotoxin immune status. Clin Int Care 1995;6:197.
Butterworth M, McClellan B, Allansmith M. Influence of sex on immunoglobulin levels (letter). Nature 1967;214:1224-5.
Eidinger D, Garrett TJ. Studies of the regulatory effects of the sex hormones on antibody formation and stem cell differentiation. J Exp Med 1972;136:1098-116.
Baumgartner J-D, Glauser M-P. Immunotherapy of endotoxemia and septicemia. Immunobiology 1993;187:464-77.
Gaffin SL, Badsha N, Brock-Utne JG, Vorster BJ, Conradie JD. An ELISA procedure for detecting human anti-endotoxin antibodies in serum. Ann Clin Biochem 1982;19:191-4.
Siber GR, Schur PH, Aisenberg AC, Weitzman SA, Schiffman G. Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. N Engl J Med 1980;303:178-82.
Yount WJ, Dorner MM, Kunkel HG, Kabat EA. Studies on human antibodies. VI Selective variations in subgroup composition and genetic markers. J Exp Med 1968;127:633-46.
Oxelius VA. Chronic infections in a family with hereditary deficiency of IgG2 and IgG4. Clin Exp Immunol 1974;17: 19-27.
Smith TF. Immunodeficiency in chronic pediatric respiratory illness. Hosp Pract 1986;15:143-58.
Kronborg G, Pressler T, Fomsgaard A, Koch C, Hoiby N. Specific IgG2 antibodies to Pseudomonas aeruginosa lipid A and lipopolysaccharide are early markers of chronic infection in patients with cystic fibrosis. Infection 1993;21: 297-302.
Cryz SJ Jr, Furer E, Sadoff JC, Fredeking T, Que JU, Cross AS. Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species. J Infect Dis 1991;163:1055-61.
Siber GR, Snydman DR. Use of immune globulins in the prevention and treatment of infections. In: Remington JS, Swartz MN, eds. Current Clinical Topics in Infectious Diseases, Vol. XII. Boston: Blackwell Scientific Publications, 1992: 208-57.
